| Literature DB >> 25559518 |
João Rafael de Oliveira Dias, Camilla Oliveira Xavier, André Maia, Nilva Simeren Bueno de Moraes, Carsten Meyer, Michel Eid Farah, Eduardo Büchele Rodrigues.
Abstract
The results of a patient with exudative age-related macular degeneration who received an intravitreal injection of ziv-aflibercept (Zaltrap; Sanofi-Aventis, Paris, France) in the right eye are described. A complete ocular examination as well as color fundus photography, optical coherence tomography, fluorescein angiography, microperimetry, full-field electroretinography, and multifocal electroretinography were performed and repeated 1 month later. The patient experienced subjective and objective improvement of visual acuity with a decrease in intraretinal and subretinal fluid. Microperimetric improvement also occurred. Electroretinographic changes were noted from baseline to the 30-day follow-up. No adverse events were observed at any time point. Ziv-aflibercept demonstrated short-term safety and efficacy after intravitreal administration for neovascular macular degeneration. Copyright 2015, SLACK Incorporated.Entities:
Mesh：
Substances：
Year: 2015 PMID： 25559518 DOI： 10.3928/23258160-20150101-17
Source DB: PubMed Journal: Ophthalmic Surg Lasers Imaging Retina ISSN： 2325-8160 Impact factor: 1.300